BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq
Executive Summary
Analysts say black box warning of anaphylaxis risk and REMS were anticipated. Company plans a gradual rollout of Palynziq, focusing first on Phase III clinical trial sites and patients.